Fig. 7From: Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancerFunctional validation of CDKN2C and RACGAP1 in PCa cells. Immunohistochemistry analysis showed that CDKN2C and RACGAP1 were more significantly upregulated in PCa patients with Gleason score >7 and pathology stage III compared to patients with Gleason score ≤7 and pathology stage II (A, B). Western blotting and bar graph show the expression and densitometric of CDKN2C and RACGAP1 knockdown in PC3 cells (C, D) and C4-2 cells (E–F). MTT (G–H) and colony formation assays (I–L) revealed that the proliferation and colony formation abilities of PC3 and C4-2 cells were significantly suppressed in response to the knockdown of CDKN2C and RACGAP1Back to article page